Nyxoah
Registration details
Company overview
Nyxoah SA is a Belgian public limited liability company (naamloze vennootschap / société anonyme) registered with the Crossroads Bank for Enterprises (KBO/BCE) under enterprise number BE 0817.149.675. Incorporated on 15 July 2009, the company’s KBO record shows an active registration. Its registered office is at Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium, which the company’s US Securities and Exchange Commission (SEC) filings also identify as its headquarters and principal executive offices.
Nyxoah SA is a medical technology company that develops and commercializes an implantable neurostimulation therapy for obstructive sleep apnea (OSA). Its lead product, the Genio system, is a leadless, battery-free hypoglossal nerve stimulator implanted to treat moderate-to-severe OSA as an alternative to continuous positive airway pressure (CPAP) therapy. The company markets the Genio system to sleep medicine and ENT specialists, with commercial and R&D activity spanning Belgium, Germany, the United Kingdom, the United States, Israel and Australia.
Nyxoah SA’s ordinary shares have traded on the regulated market of Euronext Brussels since September 2020 and on the Nasdaq Global Market in the United States, under the ticker symbol NYXH, since July 2021.
For the fiscal year ended 31 December 2025, Nyxoah SA reported consolidated net revenue of €10.0 million from Genio system sales, up from €4.5 million in fiscal year 2024, as the company scaled sales following its US market entry. As of 31 December 2025, Nyxoah SA reported 153.7 full-time-equivalent employees, down from 183.6 a year earlier, located across Europe (Belgium, Germany and the UK), the United States, Israel and Australia. For fiscal year 2026, the company has issued guidance for worldwide net revenue of €36 million to €40 million, reflecting the ongoing ramp of its US commercial launch; this figure is company guidance rather than a reported result.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Officers
30
Directors and officers of Nyxoah
Nyxoah SA’s board of directors, as listed on the company’s official website, currently comprises seven members: Robert Taub (Founder and Chairman), Prof. Pierre Gianello, Kevin Rakin, Dr. Jürgen Hambrecht, Rita Johnson-Mills, Virginia Kirby and Daniel Wildman, the latter five identified as independent directors. Executive management is led by Olivier Taelman as Chief Executive Officer, alongside named heads of finance, commercial, technology, medical, scientific, compliance, legal and international-operations functions listed on the company’s management-team page. Appointment dates for individual directors and officers were not disclosed on the pages reviewed, and none of the sources reviewed disclose the nationality of any director or executive officer. This overview reflects information published by Nyxoah SA as of 23 September 2026 and has not been cross-checked against a complete filed board-appointment history.
Recent officer changes
- Chief Financial Officer transition: John Landry, Chief Financial Officer, will step down effective 2 October 2026. Loïc Moreau, the company’s President International and a former CFO, will serve as Interim CFO from that date while a permanent successor search is conducted. Announced 21 September 2026.
Data availability
Nyxoah SA is a Belgian public company; Belgian company law does not require public disclosure of directors’ nationality or country of residence, and none was found in the sources reviewed. Officer information here reflects only current appointments as published on the company’s own website; former officers and precise appointment dates were not available from the sources reviewed.
Sources
- Nyxoah, "Board of Directors" — https://www.nyxoah.com/board-directors — retrieved 2026-09-23
- Nyxoah, "Management Team" — https://www.nyxoah.com/management-team — retrieved 2026-09-23
- StockTitan, "Nyxoah CFO John Landry to Step Down Oct. 2; Guidance Reaffirmed" — https://www.stocktitan.net/news/NYXH/nyxoah-announces-chief-financial-officer-rf6ny85jlqtr.html — published 2026-09-21 — retrieved 2026-09-23
- FinancialContent, "Nyxoah Announces Chief Financial Officer Transition" — https://www.financialcontent.com/article/gnwcq-2026-9-21-nyxoah-announces-chief-financial-officer-transition — published 2026-09-21 — retrieved 2026-09-23
Registry feed — rows exactly as filed with Crossroads Bank for Enterprises (KBO/BCE), including entries the profile above does not cover.
Group Structure
Group structure of Nyxoah
Nyxoah SA is the publicly listed parent of its corporate group; no external parent company was identified in the sources reviewed. Belgian Crossroads Bank for Enterprises (KBO/BCE) group data and the company’s SEC annual report both confirm at least one direct subsidiary, Nyxoah GmbH, incorporated in Germany. Nyxoah SA’s most recent annual report (Form 20-F for fiscal year 2025) additionally names Nyxoah Inc. (United States), Nyxoah Ltd (United Kingdom) and Nyxoah Pty Ltd (Australia) as subsidiaries, corresponding to the geographic markets in which the group reports commercial and R&D activity. Ownership percentages for these subsidiaries were not disclosed in the sources reviewed. This information reflects the company’s fiscal year 2025 annual report and KBO group data retrieved on 23 September 2026, and should be treated as partial rather than a complete, independently verified group structure.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Nyxoah GmbH | Germany | DE 60313B131221 (per KBO/BCE group data) | Direct subsidiary | Ownership percentage not disclosed | Active | 2026-09-23 |
| Nyxoah Inc. | United States | Not disclosed | Direct subsidiary | Ownership percentage not disclosed | Active | Per FY2025 Form 20-F |
| Nyxoah Ltd | United Kingdom | Not disclosed | Direct subsidiary | Ownership percentage not disclosed | Active | Per FY2025 Form 20-F |
| Nyxoah Pty Ltd | Australia | Not disclosed | Direct subsidiary | Ownership percentage not disclosed | Active | Per FY2025 Form 20-F |
Data availability
Corporate-linkage information for Nyxoah SA is partial: KBO/BCE group data and SEC annual-report disclosure confirm the existence of foreign subsidiaries, but registration numbers and ownership percentages are not fully published for all of them.
Sources
- KBO/BCE group data (Nyxoah SA cached registry linkage data, sourced from Crossroads Bank for Enterprises) — retrieved 2026-09-23
- Nyxoah SA, Form 20-F for fiscal year ended 31 December 2025 — https://www.sec.gov/Archives/edgar/data/1857190/000110465926035161/nyxh-20251231x20f.htm — retrieved 2026-09-23
Nyxoah
Belgium
Frequently asked questions
What does Nyxoah do?
Belgian medical technology company (Nyxoah SA, KBO/BCE BE 0817.149.675) that develops and commercializes the Genio system, an implantable hypoglossal nerve stimulation therapy for obstructive sleep apnea.
Who owns Nyxoah?
Major-shareholders-only disclosure under Belgian transparency rules; entities affiliated with Orin Hirchman held about 14.55% of voting rights and ResMed Inc. held about 1.95%, per transparency notifications dated 10 June 2026.
Who is Nyxoah's UBO (Ultimate Beneficial Owner)?
No verified natural-person ultimate beneficial owner identified; major disclosed holders are institutional or investment entities.
What is Nyxoah's company registration number?
Nyxoah's registration number is 0817149675, filed with Crossroads Bank for Enterprises (KBO/BCE) in Belgium. Its current status on the register is active.
Is Nyxoah still an active company?
Nyxoah's status on Crossroads Bank for Enterprises (KBO/BCE) is listed as active.
When was Nyxoah incorporated?
Nyxoah was incorporated on 15 July 2009, according to Crossroads Bank for Enterprises (KBO/BCE).
What is Nyxoah's registered address?
The registered address on file for Nyxoah is Belgium.
What legal structure is Nyxoah registered as?
Nyxoah is registered as a Public Limited Company in Belgium.
What is Nyxoah's revenue?
FY2025 consolidated net revenue of EUR 10.0 million (up from EUR 4.5 million in FY2024); FY2026 company guidance of EUR 36-40 million net revenue.
Is Nyxoah listed on a stock exchange?
Dual-listed: Euronext Brussels (since September 2020) and Nasdaq Global Market under ticker NYXH (since July 2021).
Who are the officers/directors of Nyxoah?
CEO Olivier Taelman; Chairman and founder Robert Taub; seven-member board listed on the company website; CFO John Landry departing effective 2 October 2026 with Loic Moreau as Interim CFO.
Does Nyxoah have a parent company or subsidiaries?
Nyxoah SA is the group's publicly listed parent, with subsidiaries including Nyxoah GmbH (Germany), Nyxoah Inc. (US), Nyxoah Ltd (UK) and Nyxoah Pty Ltd (Australia); ownership percentages not disclosed.